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TB incidence in South Africa remains high, despite high rates of successful 
treatment suggesting ongoing transmission and a large reservoir of latently 
infected persons. Isoniazid preventive therapy (IPT) is recommended as 
preventive therapy in HIV-infected persons. However, implementation has been 
slow, impeded by barriers and challenges including the fear of non-adherence. 
 
A protocol was therefore written to conduct a study to measure IPT completion 
rates and evaluate predictors of non-completion of a six-month IPT course in 
Khayelitsha, an informal township in Cape Town. Prior to data analysis, a 
structured literature review was conducted to assess available evidence 
particularly from high-burden settings on IPT completion rates and factors 
associated with loss to follow up. Completion rates were similar in low and high-
burden settings and varied from 47% to 81%. Treatment-, patient-, and health 
system provider-related factors identified that were associated with non-
adherence included reported isoniazid side effects, male sex, economic 














demonstrated a paucity of data from HIV-infected persons in high HIV and TB-
burden settings. 
 
The study was conducted between February 2008 and March 2010. One 
hundred and sixty four antiretroviral therapy (ART)-naïve HIV-infected patients 
with tuberculin skin test ≥5mm were recruited from Khayelitsha day hospital and 
followed up monthly. A questionnaire was used to collect demographic 
information. 
 
The overall completion rate was 69%. In multivariable analysis, self-reported 
alcohol drinkers (OR 4.05; 95% C.I. 1.89-9.06) had a four-fold higher risk of non-
completion, with a strong association between alcohol drinkers and smoking (χ2 
27.08; p<0.001). There was a 29% decrease in risk of non-completion for every 
year after HIV diagnosis (OR 0.81; 95% C.I. 0.68-0.98).  
 
Patients with a recent HIV diagnosis and self-reported drinkers and smokers 
were identified as being at higher risk of defaulting IPT, suggesting these groups 
should be identified and targeted for adherence interventions when implementing 
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PART A: PROTOCOL 
A.1 INTRODUCTION 
A.1.1 Background 
The global burden of tuberculosis (TB) remains high despite widely implemented 
strategies to control the epidemic. Sub-Saharan Africa bears the brunt of this 
burden with the World Health Organization (WHO) Africa region having the 
highest estimated incidence rate (1). This burden is exceptionally high in 
countries with generalised HIV epidemics, with HIV driving the TB epidemic 
through an increased risk of infection and reactivation disease. The annual risk 
of disease progression in HIV co-infected persons is 10% compared to a 10% 
lifetime risk in HIV negative persons (2). In South Africa, the burden of HIV-
associated TB is high with up to two thirds of TB cases occurring in HIV co-
infected persons (3). Antiretroviral therapy (ART) reduces the risk of TB in HIV 
co-infected persons but the risk of TB remains high in this population despite 
ART (4). 
 
Accurate identification and treatment of latent TB infection (LTBI) is crucial in 
order to eliminate the reservoir of infections, making prevention of TB in people 
living with HIV an urgent priority. To this end, the WHO recommends 300mg 
daily Isoniazid Preventive Therapy (IPT) for at least six months in people living 
with HIV as one of the key strategies of TB control in addition to intensified case 
finding and infection control. 
A.1.2 Problem statement  
IPT has been shown to significantly reduce the risk of incident TB predominantly 
in those with positive tuberculin skin test (TST) (5). A study compared regimens 














older 6-month IPT regimen (6). This benefit is dependent on good adherence to 
the treatment regime. 
 
Testing and treating for LTBI has predominantly been implemented in low 
burden high-income settings. However, in high TB burden settings, BCG 
vaccination and passive case-finding with treatment of microscopy/culture 
positive cases have been the cornerstones of TB control strategies with LTBI 
treatment being poorly implemented in these settings (7). Furthermore, these 
strategies could be compromised by inadequate intensified TB disease case-
finding and by low adherence. Other barriers to implementation identified include 
a lack of knowledge and experience on the part of health care workers, concerns 
regarding isoniazid (INH) resistance, and fear of side effects with hepatitis and 
peripheral neuropathy most common (8,9). Nonethel ss, the potential to interrupt 
transmission through reducing risk of reactivation and re-infection in HIV-infected 
persons makes this strategy important. 
 
The benefit of IPT in reducing incident TB has been demonstrated to be 
predominantly in TST positive people. However, it is often not feasible to perform 
the tuberculin skin test in settings with generalised HIV epidemics due to 
resource and operational constraints, further contributing to poor implementation. 
In response to this, WHO guidelines changed from have TST as a requirement 
for the diagnosis of LTBI to recommending the use of a simplified clinical 
screening algorithm to screen for active TB. The new guidelines emphasize that 
a TST is no longer a requirement for initiating IPT in people living with HIV (10). 
 
This study will aim to evaluate completion rates of IPT within a research context 
and will also aim to identify predictors of non-completion as a means of 
identifying those at high risk of non-adherence and targeting retention strategies 














A.1.3 Research question 
What are the completion rates of a 6-month course of IPT and what are the 
predictors of non-completion in an ART-naive HIV-infected cohort in Khayelitsha, 
Cape Town, recruited as part of a TB diagnostics study? 
A.1.4 Research justification 
TB remains a great burden particularly in Sub-Saharan Africa with 1% of the 
population in South Africa developing the disease annually (11). This epidemic is 
fuelled by a generalised HIV epidemic with up to two-thirds of TB cases being 
HIV co-infected (3). It is in response to these co-epidemics that the WHO 
launched the three “I”s TB control strategy comprising of infection control, 
intensified case finding and isoniazid preventive therapy. 
 
IPT has been shown to significantly decrease the incidence of TB particularly in 
tuberculin skin test (TST) positive persons. However, despite strong evidence of 
the benefit of IPT in HIV-infected adults, this strategy has not been widely 
implemented in high burden countries such as South Africa. A significant 
perceived barrier to implementation is fear of non-adherence and an increase in 
isoniazid mono-resistance and low rates of regimen completion. 
 
Research into the feasibility of completion of a 6-month regimen is therefore 
essential and few such studies have been conducted in HIV-infected patients in 
high TB/HIV burden settings. We will report on the completion rates of IPT within 
a research context. Furthermore, it is important to understand factors that may 
predispose to non-adherence to treatment in order to develop strategies 
targeting those identified as being at high risk of defaulting treatment. We will 















 To describe completion rates of IPT in a cohort of antiretroviral therapy 
naive HIV-infected persons identified as part of a larger cross-sectional 
TB diagnostics study between 01 February 2008 and 30 November 
2010. 
 To evaluate predictors of non-completion of IPT in this cohort. 
A.1.6 Summary of literature review  
We conducted a literature review using PubMed to summarise available 
evidence on completion rates and predictors of non-completion of IPT in low and 
high TB burden settings. We included all relevant studies in the English 
language that reported data on IPT completion rates and predictors of loss to 
follow up, non-adherence or non-completion. Thirteen studies met our inclusion 
criteria, five of which were conducted in high TB-burden settings (12-16). IPT 
completion rates were similar in high- and low-burden settings and varied from 
47%-78% to 45%-81% in respectively. This demonstrates that although some 
studies were conducted within research contexts, it is possible to provide IPT in 
these settings. 
 
Predictors of non-adherence can be divided into treatment-, patient- and 
provider-related barriers. 
A.1.6.1 Treatment related barriers 
Potential treatment barriers were identified in both low- and high-burden settings. 
Some studies in high-burden settings identified reported INH side effects and 
reported difficulty taking pills as being predictive of non-adherence (12,16). INH 
is known to have side effects, most common of which are peripheral neuropathy 















Studies reviewed that explored rifamycin-based regimens, which are shorter, 
were all conducted in low-burden settings. These studies reported that shorter 
regimens were more acceptable to patients and were associated with better 
adherence (17,18). As no high-burden settings conducted studies on other 
regimens, a comparison could not be made. However, a recent study evaluated 
three new regimens for LTBI treatment in South Africa in TST positive, HIV-
infected adults (6). They reported that neither a 3-month course of intermittent 
rifapentine or rifampicin with isoniazid was superior to 6 months of isoniazid at 
prevention of incident TB. In keeping with other studies, they reported lower 
adherence in the 6-month INH group compared to the rifapentine-isoniazid and 
rifampicin-isoniazid groups (84% vs 95.7% and 94.8% respectively). These 
findings suggest that new, shorter regimens could potentially improve completion 
rates and should be explored, especially in high burden countries. 
A.1.6.2 Patient related barriers 
Across the studies and settings, males were identified consistently as being at 
higher risk of non-adherence. In low-income, high-burden settings, economic 
limitations such as commuting difficulty and lack of control over resources were 
identified as significant barriers to treatment completion (14). In addition, 
education and beliefs appear to play a role in adherence. Patients who believed 
that the drugs were safe were more likely to be adherent while those who 
perceived competition between western and traditional medicines as well as 
those who struggled to take the medication due to lack of symptoms were more 
likely to be non-adherent (13,14). These factors suggest a lack of understanding 
of the purpose and potential benefit of LTBI treatment. In these cases, careful 
counselling and explanation about latent TB infection and the need for treatment 
despite lack of symptoms could potentially improve completion rates. Some 
studies also identified a lack of good support networks, HIV status non-














ART model of repeated counselling sessions prior to initiation of treatment and 
the use of treatment supporters or “buddies” could be explored in these settings 
as a strategy to tackle these barriers.  
 
In high-income settings, barriers were more related to social risk factors, with 
marginalized groups such as recent migrants, those without medical insurance 
and the homeless at higher risk of non-adherence (19). Smokers, who are at 
higher risk of TB disease, were also identified by one study as being less 
adherent that non-smokers (20).  
A.1.6.3 Health service provider related barriers 
As attendance of health facilities is necessary to access LTBI treatment, the 
relationship between patients and health care providers could influence 
completion rates. Two studies reported that outpatients and patients who 
regularly attended the clinic were less likely to be non-adherent (15,21). A poor 
relationship with the health service provider, described in focus group 
discussions as believing in the healthcare providers, could result in patients not 
attending clinic appointments resulting in non-adherence. One study specifically 
mentions a good patient/provider relationship as being predictive of completion 
of treatment (15). 
 
Moreover, we also highlight a paucity of much needed data on predictors of non-
adherence to LTBI treatment in ART-naive HIV co-infected persons attending 
















A.2.1 Study design 
This study is a longitudinal study using participants that will be identified in a 
larger cross-sectional TB diagnostics study to develop biomarkers that 
distinguish active from latent TB (REC 012/2007). As part of this larger study, 
participants with active and latent TB as well as those with other infections 
resembling TB will be recruited in both HIV-infected and uninfected cohorts. 
Latent TB (LTBI) will be diagnosed by the Mantoux test and a transverse 
induration diameter ≥5mm is considered positive in HIV-infected persons. As per 
South African national guidelines, HIV-infected persons diagnosed with LTBI will 
be initiated on Isoniazid Preventive Therapy for six months, with monthly visits to 
monitor adherence and side effects. Although this is national policy, it is not 
implemented at the health facility in Khayelitsha; therefore the author will be 
responsible for identifying eligible individuals and initiating IPT. Adherence will 
be measured by self-reported adherence, and attendance of follow-up 
appointments over the six-month period. Patients late for their appointments will 
receive a telephonic reminder and failing that, a home visit by a clinical research 
worker to encourage clinic attendance. IPT will therefore be implemented more 
within a research context than an operational clinic setting, as we will have more 
resources available to follow-up participants than might otherwise be the case in 
a regular health facility. 
A.2.2 Study setting 
The study will be conducted at site B Day Hospital, a primary care hospital in the 
informal township of Khayelitsha. Located on the outskirts of Cape Town, 















A.2.3 Population and sampling strategy 
HIV-infected persons with no signs or symptoms of active TB and with evidence 
of LTBI (TST≥5 mm) will be eligible for this study. The study population will be 
drawn from HIV-1 infected adults attending the wellness clinic at site B Day 
Hospital, between 01 February 2008 and 30 November 2010. They will either be 
newly diagnosed or attending for minor ailments, and will all be antiretroviral 
therapy (ART)- naive on account of not being eligible for ART as per the national 
guidelines at the time (CD4≥200 cells/mm3). These participants will be identified 
as the LTBI cohort of the larger TB diagnostics study. Written informed consent 
will be obtained from all participants and the University of Cape Town research 
ethics committee approved the TB diagnostics study (REC 012/2007) and the 
amendment for this study. Participants that give written consent will have a 
baseline CD4 count and induced sputum microscopy and culture performed to 
exclude active TB. A tuberculin skin test will be performed on all participants 
using 2 tuberculin units of Purified Protein Derivative (PPD) RT23 injected 
intradermally into the volar aspect of the forearm. All those with a skin induration 
diameter of ≥5 mm will have a chest x-ray performed and will be started on 
isoniazid preventive therapy for 6 months if the x-ray is normal. Non-completion 
of IPT will be defined as a failure to complete a six-month IPT course within nine 
months. As the provision of IPT in TST positive HIV-infected persons is 
compliant with national guidelines, IPT will form part of gold standard health care 
and not a research intervention. 
 
Attendance of IPT appointments will be noted, with failure to attend resulting in a 
telephonic reminder or home-visit to optimize retention. 
A.2.4 Sample size calculation 
The sample size calculation was performed for the primary TB diagnostics cross 
sectional study that aimed to develop biomarkers for active TB and was based 














expressed genes in active and latently infected TB patients. However, with a 
sample size of 164, assuming a background non-completion rate of 30%, we will 
detect a two-fold increase in the proportion of non-completers due to risk factors 
such as drinking alcohol with a power of 97%. 
 




A.2.5 Data collection  
Data collection instruments in Appendices 3 and 4. The data collection tool was 
designed for the TB diagnostics study. The variables for this study will be 
extracted from this tool. 
A.2.5.1 Study variables 
We will collect information on the measured variables for the study listed below 
in Table 1. In addition to the variables identified in the literature review, we have 
also identified variables that could potentially influence IPT completion. 
Examples include TB contact history (might be more likely to complete IPT if 
close contact with known TB case due to fear of getting sick), BMI (low BMI 
could be associated with ill-health a fear of being sick) and CD4 count (lower 
CD4 count could lead to fear of ill-health). We will compare the characteristics of 
participants with respect to the outcome (non-completion of IPT). Non-
completion (or loss to follow up) is defined as more than 3 months non-
attendance within a 9-month period from initiation of IPT. 
Variables Type Definition Categories  














Variables Type Definition Categories  
Sex Categorical  Independent Male  
Female 
Employment Categorical  Independent Employed (Employed, full-




Homemaker, Unemployed or 
seeking work, Government 
grant or pension) 
 
Marital status Categorical  Independent Single 
Married 
Educational level Ordinal Independent Grades 0-12 
Smoking Categorical  Independent Smoker (Current smoker) 
Non smoker (Never smoked, 
Ex-smoker) 
Alcohol consumption Categorical  Independent Drinker (Current drinker) 
Non-drinker (Non-drinker, Ex-
drinker ≥ 1 year, Ex-drinker < 
1 year 
Time lived in Khayelitsha Continuous Independent Months 
 
Type of dwelling Categorical  Independent Brick building 
(House/permanent building) 
Shack (Shack on serviced site, 
Shack on unserviced site or 
other open land) 
Number of persons 
sleeping/room 
Ordinal Independent 1+ 














Variables Type Definition Categories  
CD4 Continuous Independent >20 + 
Previous TB Categorical  Independent Yes  
No 
Recent TB contact Categorical  Independent Yes  
No 
BCG vaccination Categorical  Independent Yes  
No 
BMI Continuous Independent 16+ 
Mantoux induration Continuous  Independent 5+ 
Number of months IPT 
completed 
Continuous Dependent Any number 
Non-completion Categorical  Dependent Yes  
No 
Table A.1 Study variables to be measured 
A.2.6 Statistical analysis plan 
Patient baseline characteristics will be tabulated stratified by the outcome 
(completion/non-completion of IPT) and summarised using simple proportions. 
Overall completion rate of IPT will be presented as a proportion. Predictors of 
non-completion will be analysed by logistic regression. Nested models will be 
compared using the likelihood ratio test, which assesses the extent to which the 
additional terms improve the fit of the model by measuring the difference in the 
deviances of the 2 nested models. The Akaike’s Information Criterion (AIC) will 
be used to compare non-nested models with a lower AIC indicating a better 
model. The interactions between confounding and exposure variables will also 














of-fit test with a p-value >0.05 indicating a good fit of the model to the data. 
Model diagnostics will be performed on final models by checking the form of the 
linear predictors. Scatterplot diagrams of the observation number versus the 
Pearson and deviance residuals will be used to identify a systematic pattern 
which would indicate an incorrect model. Similarly, a scatterplot diagram of 
residuals versus linear predictors will be used to demonstrate good fit. In a good 
model, residuals of cases should be closer to the horizontal line as linear 
predictors get larger and vice versa for smaller linear predictors. As the 
dependent variable (non-completion) is a binary variable, the logit transformation 
is deemed appropriate and the adequacy of the link function does not require 
checking. Outlying observations will be identified as standardised residuals 
greater than +2 or smaller than -2 and scatterplot diagrams of standardised 
residuals versus the observation numbers will b  used to visually identify 
outlying observations. Influential and large leverage observations will be 
identified respectively using the Hosmer and Lemeshow test of influence (dx2) 
and hat matrix (hat), a measure of the leverage of covariate pattern i.e. how far 
the covariate pattern lies from the average covariate pattern and thus how much 
of an effect it has on the estimated model. A value greater than , where 
p=number of variables in the model and n=number of covariate patterns, is 
indicative of large leverage. Scatterplot diagrams of dx2 and hat versus the 
observation numbers will be used to visually identify influential and high leverage 
observations. The variance inflation factor (uncentered) will be used to detect 
collinearity with a VIF>>>1 suggesting multi-collinearity could be seriously 
influencing the model.  
 
Significance testing will be done using a combination of two-sided p-values and 
95% confidence intervals. All data will be analysed using STATA 10.0 














A.3 ETHICAL CONSIDERATIONS 
A.3.1 Harm 
A physician and nurse-counsellor will oversee informed consent procedures. The 
consent form will be provided in the language that the participants are most 
comfortable with. The informed consent document describes the purpose of the 
study, the procedures to be followed, and the risks and benefits of participation. 
A copy of the consent form will be given to participants. Although not a drug trial, 
this study will be conducted according to Good Clinical Practice (GCP). The 
intervention above normal care is phlebotomy for a baseline CD4 count. The 
risks of blood withdrawal are slight. Very seldom needle injury to soft tissue or 
haematoma can occur. Participants will receive a ZAR30 compensation for travel 
expenses. Study staff will receive training on the use of preventive measures to 
avoid accidental punctures with contaminated material. Counselling and, if 
indicated, emergency antiretroviral treatment will be made available to study staff 
who are accidentally exposed. 
 
Due to the sensitive nature of the data to be collected, maintaining the 
confidentiality of clinical information (including, but not limited to HIV results) is of 
high priority. Measures to ensure confidentiality will include:  
a) Recruitment and personal interviews will be done in complete privacy.  
b) Questionnaires that have a detachable section containing the person’s 
identification data.  
c) Storage of questionnaires in a locked room accessible only to select 
personnel.  
d) Computerized data will identify individuals only by code.  
















Participant autonomy will be emphasized at all times with the decision to 
participate entirely at the patient’s discretion. It will be explained to potential 
participants that a decision not to participate would not disadvantage their 
treatment in any way and that they will be free to withdraw from the study at any 
point without disadvantage. 
A.3.3 Benefit 
Participants will benefit by having a TST performed and provision of IPT in those 
diagnosed with LTBI with normal chest X-ray. Although this service is as per 
national guidelines, it is not being implemented in most government health 
facilities including the one in which the study will be conducted. Therefore 
participation in the study will result in receipt of care above the normal standard 
of care. Moreover, resources from the parent TB diagnostics study will be used 
to encourage completion of IPT through visit reminders and home visits. 
A.3.4 Confidentiality 
Due to the sensitive nature of the data collected, maintaining the confidentiality 
of clinical information (including, but not limited to HIV results) was of high 
priority. Measures to ensure confidentiality included:  
a) Recruitment and personal interviews were done in complete privacy.  
b) Questionnaires have a detachable section containing the person’s 
identification data.  
c) Storage of questionnaires in a locked room accessible only to select 
personnel.  
d) Computerized data identifies individuals only by code  















A.4 WRITE UP AND DISSEMINATION 
Implementation of IPT is poor in the Western Cape. Albeit within a research 
setting, our data will provide useful information of completion rates of IPT and 
assist in early identification of potential defaulters and development of targeted 
strategies to improve retention in care. The potential users of results generated 
from this study are other researchers, governmental and non-governmental 
organizations and the communities who are researched themselves. We will aim 
to disseminate findings at internal, national and international meetings, and in an 
open access journal. 
A.5 TIMESCALES 
Participant recruitment for this study will be conducted as part of the parent TB 
diagnostics study between February 2008 and 30 November 2010 with the last 
participant completing IPT in June 2011.  
A.6 BUDGET 
The parent TB diagnostics study is funded by the European Union with a budget 
of €4532158 (see appendix 8). Participant follow up for this study will not require 
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PART B: STRUCTURED LITERATURE REVIEW 
B.1 INTRODUCTION 
Isoniazid preventive therapy (IPT) has been shown to significantly reduce TB 
incidence, predominantly in tuberculin skin test positive persons (1,2) and at 
least six months of IPT is recommended by the World Health Organization 
(WHO) as part of the three “I”s for TB/HIV campaign (3). This strategy has 
predominantly been implemented in low-burden, high-income settings. However, 
in high TB burden settings, BCG vaccination and passive case-finding remain 
the cornerstones of TB control strategies. This slow implementation is in part due 
to fear of low adherence and non-completion of the IPT course. A better 
understanding of predictors of non-adherence would therefore facilitate targeted 
interventions to improve adherence and increase implementation of IPT in high 
burden settings. 
B.2 OBJECTIVES 
To summarise available evidence on completion rates and predictors of non-
completion of IPT in low and high TB burden settings. 
B.3 METHODOLOGY 
B.3.1 Search strategy 
We searched for primary studies and reviews from PubMed (1950 to September 
2011). Our search strategy included the following terms: “tuberculosis”, “latent 
infection”, “isoniazid”, prevent* therapy, “chemoprophylaxis”, “risk factor*”, 
“predictor*”, “adherence”, “compliance”, “complet*”. This search yielded 426 














B.3.2 Study selection and data extraction 
The search strategy aimed to identify all relevant studies in the English language 
that reported data on the population sampled, completion rates of IPT and 
predictors of loss to follow-up (LTFU) or non-adherence in the absence of 
specific interventions to improve adherence. We excluded non-English studies, 
paediatric studies, primary adherence intervention studies, primary studies that 
were included in the systematic review (n=2) and studies that did not report risk 
factors for non-adherence. We included both quantitative and qualitative studies. 
We initially aimed to restrict the studies to those from low and middle income 
countries with intermediate to high burden of disease but these criteria were 
extended due to paucity of data. Data were extracted from a subset of eligible 
studies. These include: author, country, year, study population sampled, 
proportion HIV-infected, IPT completion rates, and reported predictors of LTFU. 
B.4 RESULTS 
Of the 426 citations identified using the search strategy, 13 met our inclusion 
criteria (12 primary and 1 systematic review) and were reviewed in detail. Five 
out of 13 studies (38%) were conducted in high TB burden settings. The majority 
of studies were conducted in high income, low TB/HIV burden countries. Four 
studies were conducted solely in HIV-infected persons (4-7), all of which were in 
high disease burden settings. Completion of IPT was measured using a variety 
of methods including pharmacy refill rates, detection of INH urine metabolites, 
pill count, self-report and completion of 6-9 months IPT within a 9-12 month 
period. Two studies did not report IPT completion rates (5,8) but analysed data 
for predictors of LTFU and were thus included in our review. To allow for greater 















B.4.1 High-burden settings 
Reported IPT completion rates varied from 47.1% in rural South Africa (6) to 
78% in HIV-infected patients participating in a randomised controlled trial (RCT) 
in Botswana (4). In the latter study, the regulated trial conditions are likely to 
have contributed to higher IPT completion rates. Two studies reported male sex 
as being a risk factor for non-adherence (4,7) with men being twice as likely to 
be non-adherence and women being 3 times as likely as men to be adherent, 
respectively. Several studies reported perceived isoniazid (INH) side effects as 
being a barrier to adherence (Table B.1). Two studies explored barriers using 
qualitative techniques. Two running themes identified were stigma and economic 
barriers. Stigma was often cited as the reason for HIV status non-disclosure 
resulting in a lack of social and family support and leading to a non-acceptance 
of HIV status. Szakacs et al reported that a belief in a high chance of getting sick 
without IPT was associated with non-adherence (5). It was suggested that this 
counter-intuitive finding might be related to a perceived incurability of HIV and 
associated stigma preventing patients from taking their medication. This 
highlights a need to encourage and support patients with HIV status disclosure 
prior to IPT initiation in a similar manner to counselling offered prior to initiating 
antiretroviral therapy as an adherence improvement strategy. Economic factors 
were also cited with economic limitations, lack of transport, hunger and a lack of 
control over resources identified as barriers to adherence. 
 
It was also reported that patients who report difficulty taking meds or taking pills 
in the absence of symptoms as well as those with whom there was conflict 
between Western and traditional medicine, were more likely to be non-adherent. 
This suggests that a lack of education about the importance of IPT and 



















Risk Factors  
OR (95% CI) unless otherwise stated 
(9) Brazil TB household 
contacts 53.5% 
Non-adherence factors 
Side effects RR* 2.69 (1.3-5.8) 
Commuting difficult RR* 1.8 (1.01-3.3) 






Male 2.24 (1.24-4.04) 
Difficulty taking meds 3.4 (1.75-6.60) 












Non-adherence factors  
Time since last reported INH* dose 1.34 
(1.13-1.59) 
Belief that INH* is safe 0.34 (0.15-0.77) 
Belief in high chance of getting sick 




HIV patients on 
IPT* 




Lack of control over resources 
HIV non-disclosure and lack of social 
and family support 
Reluctance to take meds in absence of 
symptoms 



















Risk Factors  
OR (95% CI) unless otherwise stated 




≥80% of meds 
Quantitative factors for adherence 
Female 3.00 (1.56-5.88) 
History of physical symptoms 0.50 (0.32-
0.79) 
Outpatients 1.56 (1.49-2.63) 
Sex workers 0.13 (0.05-0.36) 
 
Qualitative factors for non-adherence 
HIV non-disclosure 
Out-migration 
Perceived INH* side effects 
 
Qualitative factors for adherence 
Acceptance if HIV status 
Concern about children and family 
Good health provider relationship 
Table B.1 Summary of studies conducted in high-burden settings 
*RR relative risk, RCT randomised controlled trial, INH isoniazid, IPT isoniazid 
preventive therapy. 
B.4.1 Low-burden settings 
In low disease burden settings, IPT completion rates varied from 44.6% in 
participants in an RCT to 80.8% in HIV negative patients attending TB clinics for 
IPT. Of note, the former study, an RCT conducted in the United States of 
America was based in an inner city facility with rates of unemployment and 
homelessness relatively comparable to low income settings (10). This range is 
similar to that reported in studies in high disease burden settings. Three of these 














LTBI treatment regimens to be associated with better adherence, highlighting the 
required duration of treatment as a potential barrier to treatment completion. This 
was not explored in low-income settings, therefore a comparison was not 
possible. Younger age and male sex were also identified as predictors of non-
adherence, although the systematic review of studies in USA and Canada 
reported inconsistency with respect to age as a non-adherence factor with 
studies reporting positive adherence associated with  age >65, age <35 and 
increasing age (11). Smoking is a known risk factor for TB and one study 
explored smoking as a predictor of non-adherence and reported non-smokers 
were almost twice as likely as smokers to be adherent to LTBI treatment (12). 
This study suggested that non-adherence in smokers could contribute to a 
higher risk of TB infection and disease. 
 
A running theme across a few of the studies was that social circumstances and 
marginalisation from society played a significant role in non-adherence to 
therapy. Predictors of non-adherence identified include alcohol use (especially in 
the homeless), recent immigrants, lower education, poor social support and lack 
of medical insurance (Table B.2). 
 
Reference Country Study 
population 
IPT completion Risk Factors 








Not reported Adherence factors 
Shorter LTBI* treatment regimen 4.3 (2.7-6.8) 
Non-adherence factors 
Late first visit attendance RR* 0.90 (0.8-0.98) 














Reference Country Study 
population 
IPT completion Risk Factors 
 OR (95% CI) unless otherwise stated 
(10) USA Participants 
in LTBI* 
RCT* 
44.6% Adherence factors 
Marriage 2.153 (1.301-3.5620) (+foreign birth) 
Non-adherence factors  
Alcohol use 0.53 (0.32-0.877) (+homeless) 




80.8% Non-adherence factors 
Age<36 0.33 (0.3-0.76) 
Male sex 0.58 (0.37-0.92) 
Immigrant<5years 0.21 (0.12-0.37) 
Presence of social risk factors 0.21 (0.11-0.39) 




45.2% Adherence factors 
Age≥35 RR* 1.2 (1.1-1.2) 
TB contacts RR* 1.5 (1.4-1.7) 
DOPT* RR* 1.3 (1.2-1.3) 

















Inconsistent for age with adherence assoc. 
with >65, <35 and increasing age 
TB contact 
Good social support 
Higher education 
(15) USA TB clinic 
attendants 
61.7% Non-adherence factors 
Lack of medical insurance 1.7 (1.1-2.7) 
Reported side effects 3.6 (2.2-6.2) 
Post partum 3.4 (0.9-12.6) 














Reference Country Study 
population 
IPT completion Risk Factors 
 OR (95% CI) unless otherwise stated 




72% Adherence factors 
Women 2.0 (1.2-3.3) 
 Non-smokers 1.8 (1.0-1.33) 




53.5% Adherence factors 
Choice of LTBI* treatment regimen 0.43 (0.30-
0.60) 
Clinic attendance before IPT* 0.54 (0.37-0.78) 
Age 1.04 (1.02-1.06) 
Table B.2 Summary of studies conducted in low-burden settings 
* LTBI latent tuberculosis infection, RCT randomized controlled trial, 
DOPT direct observed preventive therapy, HCW health care worker, IPT 
isoniazid preventive therapy. 
B.5 DISCUSSION 
This review presents 13 studies evaluating LTBI treatment completion rates and 
factors associated with adherence and non-adherence. The majority of studies 
assessed isoniazed based regimens as LTBI treatment with a few, in high-
income settings exploring other shorter rifamycin-based regimens. We reported 
findings stratified by disease burden of the study setting. Completion rates did 
not significantly vary between high and low burden settings. This demonstrates 
that, albeit within mainly research contexts, it is possible to provide IPT in high-
burden, low-income settings. 
 















B.5.1 Treatment-related barriers 
Potential treatment barriers were identified in both low and high burden settings. 
Some studies in high burden settings identified reported INH side effects and 
reported difficulty taking pills as being predictive of non-adherence. Most studies 
in high burden settings involved HIV-infected patients. INH is known to have side 
effects most common of which are peripheral neuropathy and drug-induced 
hepatitis, although the former is more common. 
 
Studies that explored rifamycin-based regimens, which are shorter, were all 
conducted in low burden settings. These studies reported that shorter regimens 
were more acceptable to patients and were associated with better adherence. As 
no high-burden settings conducted studies on other regimens, a comparison 
could not be made. However, a recent study evaluated three new regimens for 
LTBI treatment in South Africa in TST positive, HIV-infected adults (17). They 
reported that neither a 3-month course of intermittent rifapentine or rifampicin 
with isoniazid was superior to 6 months of isoniazid at prevention of incident TB. 
In keeping with other studies, they reported lower adherence in the 6-month INH 
group compared to the rifapentine-isoniazid and rifampicin-isoniazid groups 
(84% vs 95.7% and 94.8% respectively). These findings suggest that new, 
shorter regimens could potentially improve completion rates and should be 
explored, especially in high burden countries. 
B.5.2 Patient-related barriers 
Across the studies and settings, males were identified as being at higher risk of 
non-adherence. This may relate to gender-related differences in health-seeking 
behavior and health facility attendance patterns. In low income, high burden 
settings, economic limitations such as commuting difficulty and lack of control 
over resources were identified as significant barriers to treatment completion. In 














believed that the drugs were safe were more likely to be adherent while those 
who perceived competition between western and traditional medicines as well as 
those who struggled to take the medication due to lack of symptoms were more 
likely to be non-adherent. These factors suggest a lack of understanding of the 
purpose and potential benefit of LTBI treatment. Some studies also identified a 
lack of good support networks, HIV status non-disclosure and perceived stigma 
as barriers to treatment completion. The ART model of repeated counselling 
sessions prior to initiation of treatment and the use of treatment supporters or 
“buddies” could be explored in these settings as a strategy to tackle these 
barriers.  
 
In high-income settings, barriers were more related to social risk factors, with 
marginalized groups such as recent migrants, thos  without medical insurance 
and the homeless at higher risk of non-adherence. Smokers, who are at higher 
risk of TB disease, were also identified by one study as being less adherent that 
non-smokers. Therefore in these settings, targeting these at-risk groups for 
adherence interventions could contribute to better completion rates. 
B.5.3 Health service provider-related barriers 
Attendance of health facilities is required to receive IPT. Therefore the 
relationship between patients and health care providers could serve as a factor 
for adherence or non-adherence. Two studies reported that outpatients were 
less likely to be non-adherent. A poor relationship with the health service 
provider could result in patients not attending clinic appointments and non-
adherence. One study specifically mentions a good patient/provider relationship 














B.5.4 Strengths and limitations 
The treatment of LTBI is crucial to TB elimination, particularly in high HIV/TB 
burden settings. However implementation of this TB control strategy is poor in 
these settings. A strength of this review is its relevance to TB control in high 
burden and high transmission settings.  
 
Risk factors for non-adherence could potentially vary in different settings. 
Therefore another strength of this review is the stratification of risk factors by 
burden of disease in the study setting. This strategy highlighted key differences 
in significant predictors of treatment completion in high- and low-burden settings, 
crucial in translation of research findings into interventions t  improve completion 
rates. 
 
The majority of studies included in the review provided IPT within a research 
setting with potentially more available resources compared to the health care 
system.  
 
Only English language studies were included in this review and only one 
database was searched for studies. It is therefore likely that other published 
studies that would otherwise fit our inclusion criteria were missed. However, the 
studies that were reviewed reported similar results and we are therefore 
confident that the majority of significant predictors have been identified. 
B.6 CONCLUSION 
This review highlights a need to implement interventions to improve adherence 
alongside roll-out of LTBI treatment. We highlight patient, treatment and provider 
factors as well as specific patient groups that could be targeted in implementing 
strategies to improve IPT uptake and completion. The differences between 














strategies to the local setting in order to maximise the impact of these 
interventions. 
 
The majority of these studies were conducted within research contexts and this 
could impact on generalizability of findings. A qualitative study conducted in 
South Africa, a setting where IPT is recommended but implementation is variable 
reported a lack of provider knowledge and experience with IPT as a primary 
barrier to delivery and found that none of the patients interviewed had ever heard 
of IPT (18). This highlights the differences between research and non-research 
health care contexts and the importance of appreciating these differences in 
exploring barriers to IPT use and adherence.  
 
Moreover, we also highlight a paucity of much needed data on predictors of non-
adherence to LTBI treatment in ART-naive HIV co-infected persons attending 
HIV clinics (not within a trial context) in high-burden settings. The burden of TB is 
greatest in developing countries with generalised HIV epidemics, with a high rate 
of HIV-associated TB. This reservoir of infections further fuels the TB epidemic 
resulting in greater morbidity and mortality. Eliminating TB will therefore 
necessarily involve identifying and effectively treating HIV-infected persons 
infected with Mycobacterium tuberculosis and further research is required to 
evaluate predictors of non-completion of treatment and interventions to improve 
adherence. 
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TB incidence in South Africa remains high, despite high rates of successful 
treatment suggesting ongoing transmission and a large reservoir of latently 
infected persons. Isoniazid preventive therapy (IPT) is recommended as 
preventive therapy in HIV-infected persons. However, implementation has been 
slow, impeded by barriers and challenges including the fear of non-adherence. 
C.1.2 Objective and Methods 
The aim was to measure IPT completion rates within a research setting and to 
evaluate predictors of IPT non-completion. One hundred and sixty four 
antiretroviral therapy (ART)-naïve HIV-infected patients with tuberculin skin test 
≥5mm were recruited from Khayelitsha day hospital and followed up monthly. A 
questionnaire was used to collect demographic information. 
C.1.3 Results 
The overall completion rate was 69%. In multivariable analysis, self-reported 
alcohol drinkers (OR 4.05; 95% C.I. 1.89-9.06) had a four-fold higher risk of non-
completion, with a strong association between alcohol drinkers and smoking (χ2 
27.08; p<0.001). There was a 29% decrease in risk of non-completion for every 
year after HIV diagnosis (OR 0.81; 95% C.I. 0.68-0.98).  
C.1.4 Conclusion 
We identify patients with a recent HIV diagnosis and self-reported drinkers and 
smokers as being at higher risk of defaulting IPT, suggesting these groups 
should be identified and targeted for adherence interventions when implementing 















Tuberculosis (TB) is an ever-expanding threat to global public health, despite the 
availability of efficacious treatment, with a third of people estimated to be latently 
infected worldwide, 33.2 million with HIV infection (1). HIV-1 (HIV) is the 
strongest known risk factor for TB and where these pandemics intersect, they 
are the most common cause of death among young adults in many countries. 
Sub-Saharan Africa bears the brunt of this burden with the World Health 
Organization (WHO) Africa region having the highest estimated incidence rate 
(2). This burden is exceptionally high in countries with generalised HIV 
epidemics with HIV driving the TB epidemic through an increased risk of 
infection and reactivation disease. 
 
In response to these dual epidemics, the WHO’s STOP TB strategy to 
dramatically reduce the global burden of TB by 2015, recommends collaborative 
HIV/TB activities including the three “I”s for HIV/TB: Intensified Case-Finding 
(ICF), Isoniazid Preventive Therapy (IPT), and Infection Control in addition to 
antiretroviral therapy (ART). IPT has been shown to significantly reduce the risk 
of incident TB (3) predominantly in those with positive tuberculin skin test. This 
benefit is dependent on good adherence to the treatment regime. While ART roll-
out has been expanding, implementation of ICF and IPT have been slow, 
impeded by barriers and challenges. This lack of implementation is in part due to 
fear of non-adherence. 
 
South Africa is a high TB burden setting with an estimated incidence rate in 2010 
of 981/100,000, and with 60% of TB cases occurring in HIV-infected persons (4). 
This makes IPT crucial to TB control in this high-burden setting. IPT is slowly 
being implemented in the public health sector. WHO estimates of the number of 
people on IPT in South Africa show an increase from 7359 in 2008 to 23,589 














to receive IPT. Furthermore, this does not elaborate on the proportion of persons 
initiating IPT that complete the course. This highlights a need for data on 
completion rates and research evaluating barriers to implementation in the public 
health sector as well as identifying possible predictors of non-completion of IPT 
amongst eligible persons. 
 
We present the findings of a study examining completion rates of IPT within a 
research context and evaluated patient-related predictors of non-completion as a 
means of identifying those at high risk of non-adherence and targeting retention 
strategies at these persons. 
C.3 METHODS 
C.3.1 Study design, setting and population 
Participants in this study were identified from a larger cross-sectional TB 
diagnostics study to develop biomarkers that distinguish active from latent TB 
and other infections. The study was conducted at site B Day Hospital, a primary 
care health facility in the informal township of Khayelitsha. Located 30km from 
Cape Town, Khayelitsha has a population of over 400,000 and a TB case 
notification rate of over 1600/100 000, 70% of which occur in HIV co-infected 
persons (6). 
C.3.2 Sampling and recruitment strategy 
Study participants were recruited from the HIV wellness clinic, comprised of 
patients newly diagnosed with HIV and those not eligible for antiretroviral therapy 
(ART) at Khayelitsha day hospital, between February 2008 and March 2010. 
Written informed consent was obtained from all participants recruited as part of a 
larger TB diagnostics study. This study was approved by the University of Cape 
Town health research ethics committee (REC 012/2007). Participants were 














for minor ailments. Consecutive patients attending the clinic without any 
symptoms of TB were invited to participate and tested for evidence of latent TB. 
One hundred and sixty four persons were identified with a skin induration 
diameter of ≥5mm and no evidence of active TB disease. With a sample size of 
164, assuming a background non-completion rate of 30% based on available 
data from Southern Africa, we could detect a two-fold increase in the proportion 
of non-completers due to risk factors such as drinking alcohol with a power of 
97%.  
C.3.3 Measures 
Latent TB (LTBI) was diagnosed in these HIV-infected persons by the tuberculin 
skin test (TST) using 2 TU of tuberculin PPD RT23 injected intradermally into the 
volar aspect of the forearm. A transverse induration diameter ≥5mm was 
considered as evidence of LTBI. At recruitment, all participants were also 
screened for TB with sputum microscopy and culture to exclude active TB 
disease and a baseline CD4 count performed.  
 
All participants were commenced on IPT for six months, as per South African 
national guidelines, with monthly visits to monitor adherence and side effects. 
Adherence was measured by self-reported adherence, and attendance of follow-
up appointments. Self-reported adherence was measured by asking patients if 
they took the pills as prescribed everyday in the preceding month, and was 
ascertained at monthly visits by the same investigator. Patients who missed an 
appointment received daily telephonic reminder and failing that after a week, a 
home visit by the trained clinical research assistant to encourage clinic 
attendance. Non-completion of IPT (outcome variable) was defined as a failure 















In addition, a questionnaire, applied by trained study personnel, was used to 
collect baseline demographic information including age, employment status, 
alcohol consumption, smoking status, past TB history, recent TB contact, type of 
accommodation lived in, and date of HIV diagnosis. This questionnaire was 
designed for the larger TB diagnostics study and data for this study extracted 
from the database.  
C.3.4 Hypothesis 
We hypothesized, based on existing literature, that being male, employed, 
consuming alcohol and smoking would be predictors of non-completion of IPT. 
C.3.5 Statistical analysis 
Patient baseline characteristics were stratified by outcome and summarised 
using simple proportions. Predictors of non-completion were analysed by logistic 
regression and nested models compared using the likelihood ratio test. The Chi 
squared test was used to compare proportions. The Akaike’s Information 
Criterion (AIC) was used to compare non-nested models with a lower AIC 
indicating a better model. The interactions between confounding and exposure 
variables were then examined. The fit of the model was assessed using 
Pearson's goodness-of-fit test with a p-value >0.05 indicating a good fit. Model 
diagnostics were performed on final models by checking the form of the linear 
predictors. 
 
Significance testing was done using two-sided p-values and 95% confidence 
















C.4.1 Baseline characteristics and IPT completion rate 
Of the one hundred and sixty four participants identified with LTBI, all accepted, 
and were initiated on, IPT.  Overall, one hundred and thirteen persons (69%) 
completed the six-month IPT course. For the first thirty-three patients initiated on 
IPT, adherence was encouraged by explaining that the benefits of IPT could only 
be achieved if the course was completed. This message was delivered by the 
same study doctor in a standardized manner at monthly follow-up visits. In this 
group, the IPT completion rate was 42% with eighteen out of thirty-three (58%) 
not completing the full IPT course. The subsequent use of a research assistant 
resulted in an improvement in completion rates; of the one hundred and thirty 
one patients recruited thereafter, 75% completed IPT. 
 
Baseline characteristics were compared, stratified by completion or non-
completion of a six-month course of IPT, and summarized in Table C.1. Amongst 
those that did not complete the IPT course, a median of two months IPT (IQR 0-
3 months) was completed. Compared to those who completed IPT, patients who 
did not complete the course had a higher proportion of smokers (21.6% versus 
9.7%; p=0.04) and alcohol drinkers (37.2% versus 14.2%; p=0.001). They were 
more likely to have been recently diagnosed with HIV (median time since HIV 
diagnosis 54 days (IQR 6-910) versus 421 days (IQR 43-1479); p=0.002). There 
were also a higher proportion of men versus women (22.4% versus 15%; 
p=0.252) in the non-completers group. Similarly, a greater proportion of non-
completers were recent migrants to Khayelitsha (11.9% versus 5.3%; p=0.155) 
although numbers were small. The distribution of all other measured baseline 






























28   (17.3) 
Marital status Single 
Married 























35   (21.3) 





5   (4.4) 
41 (80.4) 
10 (19.6) 
0   (0.0) 
119 (72.6) 
40   (24.4) 
5     (3.0) 





6   (11.8) 
143 (87.2) 
21   (12.8) 
















7   (13.7) 
30   (18.3) 
113 (68.9) 















87 (56.1)  68 
(43.9) 
Time in Khayelitsha <1 year 
>=1 year 
6     (5.3) 
107 (94.7) 
5   (11.9) 
37 (88.1) 
11  (7.1) 
144 (92.9) 
Characteristics  Median (IQR) Median (IQR) Median (IQR)  





























 360 (269-508) 363 (261-526) 361 (266-515) 
Years since HIV 
diagnosis 








 20 (15-24) 20 (12-24) 20 (15-24) 
Total number of 
months IPT completed 
 6 (6-6) 2 (0-3) 6 (3.5-6) 
Table C.1 Baseline characteristics stratified by completion and non-completion of 
IPT 
C.4.2 Predictors of non-completion of IPT 
On bivariable analysis, being male, smoking, alcohol, and a recent HIV diagnosis 
were associated with an increased risk of IPT non-completion (Table C.2). There 
was a significant association between being male and drinking alcohol (χ2 9.76; 
p=0.002) and smoking (χ2 31.12; p<0.001). There was also a strong association 















 Univariable analysis Multivariable analysis 
OR (95% C.I.) P-value OR (95% C.I.) P-value 
Alcohol  
 
4.66 (2.03-10.69) <0.001 4.05 (1.89-9.06) 0.001 
Years since HIV 
diagnosis 
0.82 (0.67-0.99) 0.038 
 
0.81 (0.68-0.98) 0.030 
Smoker 3.59 (1.41-9.18) 0.008   
Gender 2.34 (0.97-5.64) 0.058   
TB contact  0.54 (0.23-1.26) 0.152   
Previous TB 0.94 (0.32-2.79) 0.910   
BCG Scar 0.92 (0.44-1.94) 0.832   
Self-reported BCG 1.13 (0.58-2.22) 0.720   
Employed 0.85 (0.39-1.84) 0.680   
Accommodation 1.46 (0.69-3.06) 0.323   
Time in Khayelitsha 0.39 (0.11-1.36) 0.138   
Marital status 0.93 (0.40-2.14) 0.862   
Age (years) 0.99 (0.94-1.04) 0.597   
BMI 0.96 (0.90-1.02) 0.186   
Education 1.07 (0.90-1.29) 0.440   









0.132   
Table C.2 Bivariable and multivariable analysis using non-completion of IPT as 
the outcome variable 
On multivariable analysis the period of time since HIV diagnosis and drinking 
alcohol remained significant with a four fold increase in odds of non-completion 
in drinkers compared to non-drinkers and a 19% decrease in odds of non-















Due to the strong association between smoking and drinking we chose to include 
the alcohol variable, as its inclusion in the model resulted in a marginally better 
fit of the model to the data using the Pearson goodness of fit test compared to a 
model that included smoking. However, given the association between these two 
variables, both should be considered in the interpretation of these results. There 
was no significant effect modification between sex and drinking or smoking 
although it should be noted that a greater proportion of male versus female 
participants reported being smokers (46% versus 7%) and drinkers (43% versus 
16%). 
 
We further explored the relationship between the period of time since HIV 
diagnosis and non-completion of IPT by examining the proportion of non-
completers stratified into four time periods since HIV diagnosis (<6 months, 6-12 
months, 1-5 years, and >5 years since HIV diagnosis). Figure C.1 shows that 
non-completers were most likely to default IPT if initiated within six months of 
HIV diagnosis compared to persons initiated after >six months post-HIV 
















Figure C.1 Histogram showing the proportion of IPT non-completers stratified by 
time period since HIV diagnosis. N represents the total sample size 
of participants in each time period 
C.5 DISCUSSION 
We report a 69% IPT completion rate in this ART-naïve HIV-infected population 
in Cape Town. Studies conducted in similar high burden settings have reported 
IPT completion rates from 47% in HIV-infected adults attending clinics in 
Limpopo, rural South Africa to 78% in participants involved in a randomized 
controlled trial in Botswana (7,8). In the latter study, the regulated trial conditions 
are likely to have contributed to higher IPT completion rates.  
 
We also explored quantitative patient predictors of non-completion of IPT and 
found a recent HIV diagnosis and self-reported alcohol drinking and smoking to 














for non-completion have reported male patients as being at risk of non-
completion (8,9) with men being twice as likely to be non-completers and women 
being three times as likely as men to complete the course, respectively. Studies 
have also reported perceived INH side effects as being a barrier to adherence 
(9,10). One study examining qualitative barriers to IPT completion reported that 
patients who reported difficulty taking meds or taking pills in the absence of 
symptoms as well as those in whom there was conflict between Western and 
traditional medicine, were more likely to be non-adherent (7). This suggests that 
a lack of education about the importance of IPT and explanation about 
prevention of TB might contribute to non-adherence. In our study, prior to the 
use of telephonic reminders, our completion rate was 42%, increasing to 75% 
with the use of reminders. These reminders could therefore serve as an 
opportunity to educate patients on the importance of completing IPT, despite the 
absence of symptoms. 
 
We found patients with a more recent HIV diagnosis had a higher risk of non-
completion. This could relate to non-acceptance of HIV status and a resulting 
reluctance to attend follow-up appointments. It could also relate to non-
disclosure of HIV status to friends and family and wanting to keep their HIV 
status confidential, resulting in an unwillingness to attend the health facility. A 
study conducted in Thailand reported acceptance of personal HIV status as a 
predictor of adherence (9). Patients established in HIV clinics are more likely to 
have accepted their HIV status and developed a habit of attending the health 
facility for routine appointments and for minor ailments, which could facilitate IPT 
adherence. In addition, this could be related to their perceived risk and lack of 
education on HIV opportunistic infections such as TB. 
 
We also reported alcohol drinking and smoking as risk factors for non-completion 














burden settings (11,12). In this high-burden setting, this association possibly 
relates to marginalization representing a social risk factor. This was 
demonstrated by a study in Spain that reported an association between non-
adherence and patients with unfavourable social circumstances such as alcohol 
and drug abuse and recent immigrants (13). 
 
Based on existing literature, we hypothesized that male and unemployed 
patients would also be at higher risk of non-completion. Unemployment rates are 
high in Khayelitsha and this could explain why employment was not associated 
with adherence in our study. Sixty-five percent of drinkers and 59% of smokers 
were male suggesting that the expected association between male sex and non-
completion of IPT could relate to a greater proportion of alcohol drinkers and 
smokers within this group and could explain why being male was not a 
significant risk factor in this study. 
C.5.1 Limitations 
Although IPT follow-up was conducted within the health facility, it was conducted 
within a research context and this could limit the generalizability of our findings in 
under-resourced settings. Furthermore, completion of IPT was based on self-
reported adherence. This could result in an over-estimation of completion rates. 
Several studies have examined barriers to IPT roll-out in high burden settings. 
Healthcare worker related barriers were identified by Getahun et al, with lack of 
experience and knowledge of current guidelines cited as an important barrier (5). 
Other barriers to implementation identified include concerns about INH 
resistance, and fear of side effects with hepatitis and peripheral neuropathy most 
common (9,14). Our study did not examine health system factors, such as a 
good patient-health provider relationship, which could play a significant role in 














C.6 CONCLUSION AND RECOMMENDATIONS 
The WHO has identified IPT as one of the main interventions to reduce morbidity 
and mortality from TB in people living with HIV. A better understanding of 
predictors on non-adherence to IPT is therefore crucial to optimize adherence in 
high HIV/TB burden settings. Implementation of IPT has been slow in South 
Africa. The findings of this study are therefore important as the completion rate 
reported demonstrates the potential feasibility of providing IPT in this setting. 
The identification of a recent HIV diagnosis as a significant predictor of non-
completion suggests that in this setting, IPT should not be initiated in HIV-
infected persons too soon after diagnosis. Our results also suggest that when 
initiating IPT, the smoking and alcohol history of patients should be ascertained, 
with targeted adherence interventions implemented aimed at those who smoke 
or drink and those with a more recent HIV diagnosis. We found IPT completion 
improved with the use of a research worker suggesting that in the implantation of 
IPT in this setting, adherence interventions using lay community workers to give 
reminders of appointments and continuous education could improve IPT 
completion. 
 
Key areas for future research include into health systems barriers and the impact 
of adherence interventions, such as community supporters as part of an 
integrated chronic disease management package, in improving rates of IPT 
completion.  
C.7 ACKNOWLEDGEMENTS 
The primary study was funded by a grant from the European Union 
(Sante/2006/105-061) and Bill and Melinda Gates Foundation GC 6-74 37772. 
The funders did not play a role in the design of the study or preparation of the 
manuscript. Relebohile Tsekela, Bekekile Kwaza and Lulama Manjezi 


































1. Corbett E, Watt C, Walker N, Maher D, Williams B, Raviglione M, et 
al. The growing burden of tuberculosis: global trends and interactions 
with the HIV epidemic. Arch Intern Med. 2003;163(9):1009–1021.  
2. Dye C. Global epidemiology of tuberculosis. Lancet. 
2006;367(9514):938–940.  
3. Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, 
et al. 6-month versus 36-month isoniazid preventive treatment for 
tuberculosis in adults with HIV infection in Botswana: a randomised, 
double-blind, placebo-controlled trial. Lancet. 2011;377(9777):1588–
1598.  
4. WHO. Global Tuberculosis Control. Geneva: World Health 
Organization; p. 1–258.  
5. Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, et 
al. Implementation of isoniazid preventive therapy for people living 
with HIV worldwide: barriers and solutions. AIDS. 2010;24 Suppl 
5:S57–65.  
6. Médecins Sans Frontierès. Summary: Khayelitsha Activity Report 
2001-2011. http://www.msf.org.za/publication/summary-khayelitsha-
activity-report-2001-2011. Accessed 2012 Jan. 24. 
7. Rowe KA, Makhubele B, Hargreaves JR, Porter JD, Hausler HP, 
Pronyk PM. Adherence to TB preventive therapy for HIV-positive 
patients in rural South Africa: implications for antiretroviral delivery in 














8. Gust DA, Mosimaneotsile B, Mathebula U, Chingapane B, Gaul Z, 
Pals SL, et al. Risk Factors for Non-Adherence and Loss to Follow-
Up in a Three-Year Clinical Trial in Botswana. PLoS ONE. 
2011;6(4):e18435.  
9. Ngamvithayapong J, Uthaivoravit W, Yanai H, Akarasewi P, 
Sawanpanyalert P. Adherence to tuberculosis preventive therapy 
among HIV-infected persons in Chiang Rai, Thailand. AIDS. 
1997;11(1):107–112.  
10. Szakacs TA, Wilson D, Cameron DW, Clark M, Kocheleff P, Muller 
FJ, et al. Adherence with isoniazid for prevention of tuberculosis 
among HIV-infected adults in South Africa. BMC Infect Dis. 
2006;6(1):97.  
11. Hirsch-Moverman Y, Bethel J, Colson PW, Franks J, El-Sadr W. 
Predictors of latent tuberculosis infection treatment completion in the 
United States: an inner city experience. Int J Tuberc Lung Dis. 
2010;14(9):1104–1111.  
12. Lavigne M, Rocher I, Steensma C, Brassard P. The impact of 
smoking on adherence to treatment for latent tuberculosis infection. 
BMC Public Health. 2006;6(1):66.  
13. Anibarro L, Casas S, Paz-Esquete J, Gonzalez L, Pena A, Guerra 
MR, et al. Treatment completion in latent tuberculosis infection at 
specialist tuberculosis units in Spain. Int J Tuberc Lung Dis. 
2010;14(6):701–707.  
14. Machado A, Finkmoore B, Emodi K, Takenami I, Barbosa T, Tavares 














tuberculosis infection treatment in Salvador, Brazil. Int J Tuberc Lung 















PART D: APPENDICES 
APPENDIX 1- DETAILED STATISTICAL ANALYSIS 
Patient baseline characteristics were tabulated stratified by the outcome 
(whether or not they were lost to follow up) and summarised using simple 
proportions. Overall completion rate of IPT was presented as a proportion. 
Predictors of loss-to-follow-up were analysed by logistic regression. Nested 
models were compared using the likelihood ratio test, which assesses the extent 
to which the additional terms improve the fit of the model by measuring the 
difference in the deviances of the 2 nested models. The Akaike’s Information 
Criterion (AIC) was used to compare non-nested models with a lower AIC 
indicating a better model. The interactions between confounding and exposure 
variables were then examined. The fit of the model was assessed using 
Pearson's goodness-of-fit test with a p-value >0.05 indicating a good fit of the 
model to the data. Model diagnostics were performed on final models by 
checking the form of the linear predictors. Scatterplot diagrams of the 
observation number versus the Pearson and deviance residuals, were used to 
identify a systematic pattern which would indicate an incorrect model. Similarly, a 
scatterplot diagram of residuals versus linear predictors was used to 
demonstrate good fit. In a good model, residuals of cases should be closer to the 
horizontal line as linear predictors get larger and vice versa for smaller linear 
predictors. As the dependent variable (loss to follow up) is a binary variable, the 
logit transformation was deemed appropriate and the adequacy of the link 
function did not require checking. Outlying observations were identified as 
standardised residuals greater than +2 or smaller than -2 and scatterplot 
diagrams of standardised residuals versus the observation numbers were used 
to visually identify outlying observations. Influential and large leverage 
observations were identified respectively using the Hosmer and Lemeshow test 














pattern i.e. how far the covariate pattern lies from the average covariate pattern 
and thus how much of an effect it has on the estimated model. A value greater 
than , where p=number of variables in the model and n=number of covariate 
patterns, was indicative of large leverage. Scatterplot diagrams of dx2 and hat 
versus the observation numbers were used to visually identify influential and 
high leverage observations. The variance inflation factor (uncentered) was used 
to detect collinearity with a VIF>>>1 suggesting multi-collinearity could be 
seriously influencing the model.  
 
Significance testing was done using a combination of two-sided p-values and 
95% confidence intervals. All data were analysed using STATA 10.0 (StataCorp, 





















  Likelihood ratio test 
     χ
2
                  p-value        Vs. 
AIC 
A LTFU -83.71 0.00 . . . 169.416 
B LTFU + Age -83.57 0.28 0.28 0.595 A 171.101 
C LTFU + Sex -81.97 3.47 3.47 0.063 A 167.946 
D LTFU + BMI -82.79 1.83 1.83 0.176 A 169.588 
E LTFU + Smoker -80.23 6.96 6.96 0.008 A 164.459 
F LTFU + Previous TB  -83.70 0.01 0.01 0.910 A 171.403 
G LTFU + BCG Scar -83.69 0.05 0.05 0.832 A 171.371 
H LTFU + TB contact -82.55 2.31 2.31 0.129 A 169.107 
I LTFU + Education -83.39 0.63 0.63 0.427 A 170.784 
J LTFU + Employment -83.62 0.17 0.17 0.679 A 171.245 
K LTFU +Informal housing -83.22 0.98 0.98 0.323 A 170.439 
L  LTFU+ Overcrowding -83.47 0.49 0.49 0.486 A 170.930 
M LTFU+ Time in 
Khayelitsha 
-82.66 2.10 2.10 0.148 A 169.318 
N LTFU + CD4 count  -83.58 0.26 0.26 0.613 A 171.161 
O LTFU+ Days with HIV -81.18 5.05 5.05 0.025 A 166.365 
P LTFU+ Years with HIV -81.19 5.04 5.04 0.025 A 166.371 
Q LTFU+ Self reported 
BCG 
-83.64 0.13 0.13 0.720 A 171.288 
R LTFU+ Alcohol drinker -77.11 13.19 13.19 <0.001 A 158.228 
S LTFU+ Mantoux 
diameter 
-82.59 2.24 2.24 0.134 A 169.173 
T LTFU+ Marital status -83.69 0.03 0.03 0.862 A 171.386 
DROP HIV YEARS       
R LTFU+ Alcohol drinker -77.11 13.19 13.19 <0.001 A 158.228 
U LTFU+ Alcohol drinker+ 
Smoker 
-76.30 14.81 1.62 0.203 R 158.605 
V LTFU+ Alcohol 
drinker+ Days with HIV 
-74.63 18.16 4.97 0.026 R 155.255 
W LTFU+ Alcohol drinker+ 
Sex 
-76.60 14.22 1.03 0.311 R 159.201 
X LTFU+ Alcohol drinker+ 
TB contact 
-76.31 14.79 1.60 0.206 R 158.627 
Y LTFU+ Alcohol drinker+ 
Mantoux diameter 
-75.58 16.25 3.06 0.080 R 157.165 
Z LTFU+ Alcohol drinker+ 
Time in Khayelitsha 
-75.75 15.91 2.72 0.099 R 157.505 
AA LTFU+ Alcohol 
drinker+ BMI 
-76.79 13.83 0.64 0.423 R 159.587 
AB LTFU+ Alcohol 
drinker+ Informal housing 
-76.38 14.65 1.46 0.227 R 158.767 
AC LTFU+ Alcohol 
drinker+ Education 
-76.74 13.93 0.74 0.389 R 159.485 
AD LTFU+ Alcohol 
drinker+ Overcrowding 
-76.93 13.55 0.37 0.545 R 159.862 
AE LTFU+ Alcohol 
drinker+ Age 
-76.99 13.45 0.27 0.606 R 159.962 
AF LTFU+ Alcohol 
drinker+ CD4 count 














AG LTFU+ Alcohol 
drinker+ Employment 
-76.97 13.48 0.30 0.587 R 159.932 
AH LTFU+ Alcohol 
drinker+ Self reported BCG 
-77.08 13.26 0.07 0.785 R 160.154 
AI LTFU+ Alcohol drinker+ 
BCG scar 
-77.10 13.21 0.02 0.879 R 160.205 
AJ LTFU+ Alcohol drinker+ 
Marital status 
-77.11 13.19 0.00 0.976 R 160.227 
AK LTFU+ Alcohol 
drinker+ Previous TB 
-77.11 13.19 0.00 0.984 R 160.228 
       
V LTFU+ Alcohol 
drinker+ Days with HIV 
-74.63 18.16 4.97 0.026 R 155.255 
AL LTFU+ Alcohol drinker+ 
Days with HIV+ Mantoux 
diameter 
-73.34 20.73 2.57 0.109 V 154.685 
AM LTFU+ Alcohol 
drinker+ Days with HIV+ 
Time in Khayelitsha 
-73.69 20.03 1.87 0.171 V 155.384 
AN LTFU+ Alcohol 
drinker+ Days with HIV+ 
Smoker 
-74.11 19.19 1.03 0.310 V 156.223 
AO LTFU+ Alcohol 
drinker+ Days with HIV+ 
TB contact 
-74.11 19.19 1.03 0.311 V 156.227 
AP LTFU+ Alcohol 
drinker+ Days with HIV+ 
Informal housing 
-74.18 19.05 0.89 0.347 V 156.369 
AQ LTFU+ Alcohol 
drinker+ Days with HIV+ 
Sex 
-74.51 18.39 0.23 0.629 V 157.021 
AR LTFU+ Alcohol 
drinker+ Days with HIV+ 
Education 
-74.18 19.06 0.90 0.342 V 156.352 
AS LTFU+ Alcohol 
drinker+ Days with HIV+ 
BMI 
-74.504 18.41 0.25 0.619 V 157.008 
AT LTFU+ Alcohol 
drinker+ Days with HIV+ 
Overcrowding 
-74.49 18.44 0.28 0.595 V 156.972 
AU LTFU+ Alcohol 
drinker+ Days with HIV+ 
Employment 
-74.39 18.64 0.48 0.489 V 156.777 
AV LTFU+ Alcohol 
drinker+ Days with HIV+ 
Age 
-74.37 18.67 0.51 0.474 V 156.743 
AW LTFU+ Alcohol 
drinker+ Days with HIV+ 
Self reported BCG 
-74.61 18.19 0.03 0.857 V 157.223 
AX LTFU+ Alcohol 
drinker+ Days with HIV+ 
BCG scar 
-74.60 18.21 0.05 0.825 V 157.206 
AY LTFU+ Alcohol 
drinker+ Days with HIV+ 
CD4 count 
-74.62 18.18 0.01 0.906 V 157.241 
AZ LTFU+ Alcohol 
drinker+ Days with HIV+ 
Marital status 














BA LTFU+ Alcohol 
drinker+ Days with HIV+ 
Previous TB 
-74.63 18.16 0.00 0.952 V 157.251 
 
. /*FINAL MODEL*/ 
. logistic ltfu drinker hivdays 
 
Logistic regression                               Number of obs   =        158 
                                                  LR chi2(2)      =      17.54 
                                                  Prob > chi2     =     0.0002 
Log likelihood = -87.405166                       Pseudo R2       =     0.0912 
 
------------------------------------------------------------------------------ 
        ltfu | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     drinker |    4.04804   1.663666     3.40   0.001     1.808912     9.05883 
     hivdays |   .9994392   .0002582    -2.17   0.030     .9989334    .9999453 
------------------------------------------------------------------------------ 
 
. logistic ltfu drinker hivyears 
 
Logistic regression                               Number of obs   =        158 
                                                  LR chi2(2)      =      17.54 
                                                  Prob > chi2     =     0.0002 
Log likelihood = -87.405588                       Pseudo R2       =     0.0912 
 
------------------------------------------------------------------------------ 
        ltfu | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
     drinker |    4.04913   1.664135     3.40   0.001     1.809381    9.061361 



















APPENDIX 3- DATA COLLECTION TOOL FOR THE TB DIAGNOSTICS, CROSS-SECTIONAL 
PARENT STUDY 
 
QID Question Code of Response Coded Response 
Demographics, Socio-Economic Status and Social Habits 
1 Sex? 1= Male 
2= Female  
 
2 Date of birth? (dd/mmm/yyyy) 
09/SEPT/1999=Unknown 
 
3 Relationship status: 1=single 










5= Other (specify)…. 
 








3= Unemployed or seeking work 
4= Employed, full-time 
5= Employed, part-time 
6= Employed, casual 
7= Self-employed 
8= Government grant/pension 
 
5b If employed, what kind of 










6 What is your smoking habit? 1= Current smoker 
2= Ex-smoker 
3= Never smoked 
if ex-smoker, when quit 
 
Quantity / day………………… 





















4= Other (Specify) 
 
 
8a Do you drink beer, wine or 
other alcoholic beverages, 




3=Ex drinker ≥ 1 year 
4=Ex Drinker < 1 year 




8b Have you ever felt the need 
to Cut down on your 
drinking? 
1=Yes    
2=No 
 
8c Have people Annoyed you 
by criticizing your drinking? 
1=Yes    
2=No 
 
8d Have you ever felt bad or 
Guilty about your drinking? 
1=Yes    
2=No 
 
8e Have you ever had a drink 
first thing in the morning (Eye 
opener) to steady your 
nerves or get rid of a 
hangover? 




9 If subject answered yes to 
any TWO of Q8 a,b,c, or d, 
subject may be considered to 
have an alcohol problem. 




10 During the last month, 
average number of units of 
alcohol per day during the 


























12 What type of accomodation 
do you live in? 
1= House/permanent building 
2= Shack on serviced site (e.g water 
on site)  
3= Shack on unserviced site or other 
open land (ie nothing available) 
4= Other 
(specify)……………………………. 
9= Don’t Know 
 
13 How many rooms are there in 
the house? 01-20 
 
14 How many rooms are used 
for sleeping? 
01-20  







16 Are you currently pregnant? 1=Yes         
2=No        
7=N/A (Male)  
9= Don’t know 
 






HIV and TB History 
17 Did you receive BCG as a 
baby?  
1=Yes    
2=No 
9= Don’t know 
 
18 Previous TB? 1=Yes    
2=No 
9= Don’t know 
If NO, skip to Q24 
 





20 When did you last have TB? 1= Past 6 months 
2 = Past 6-12 months 
3 = Past 12-24 months 
4 = >24 months ago 
 















21 Have you ever received 
treatment for TB? 
1=Yes    
2=No 
9= Don’t know 
 
22 The last time you had TB; did 
you complete your TB 
treatment? 
1=Yes    
2=No 
9= Don’t know 
 
23 The last time you had TB, 
how many months of TB 




24 Has anyone close to you had 







Nature of contact  …………………………………………… 
Date of contact     …………………………………………….          







If known, specify date:  mmm/yyyy 
 




27 HIV results seen? 1=Yes    
2=No 
 
28 If HIV positive, date of HIV 
diagnosis?  
 
                                       MMM / YYYY 








 for how long?          …………………………………………. 
Past Medical History 
30 Do you have Hypertension? 1=Yes 
2=No 














31 Do you have Diabetes? 1=Yes 
 
2=No 
9= Don’t know 
 
32 Do you have epilepsy? 1=Yes 
2=No 
9= Don’t know 
 Drug History 
33 Are you currently taking any 
medications from the doctor, 



















Signature of person completing form and Date____      ____/  ____   /________ 















APPENDIX 4- DATA COLLECTION TOOL FOR IPT FOLLOW UP 
 
                                                      INH FOLLOW-UP VISIT NO:  
OBS 
Temp PR Weight BP 
    
 
Date last INH received  
Months completed on INH  
CURRENT SYMPTOMS 





SYMPTOMS Y/N            Duration 
Cough   
Blood in sputum   
SOB   
Pleuritic pain   
Night sweats   
   
   
   
   
INH SIDE-EFFECTS   
P. neuropathy   
Jaundice   
 ON EXAMINATION 





















SYMPTOMS BETWEEN VISITS  
















Cough         
Blood in sputum         
Pleuritic pain         
SOB         
         
Did you get 
antibiotics? 
       
Were you screened 
for TB  D/C/S? 
   Were you screened 
for TB  D/C/S? 
  
Did you need hospital 
admission? 
   Did you need 
hospital admission? 
  
If yes, complete table below: 
 
List investigations required, if any 
…....................................................................................................... 
TB D/C/S required?       Y / N                           
CXR required?               Y / N 
INH month  …… / 6 months; prescribed / withheld (circle as appropriate). Pyridoxine 
25mg given ✓ / ✗   
Other medication 
prescribed……………………………………………………….……………… …… 
Next appointment date: __ __/ __ __ __/__ __ __ __   If INH course complete, CD4 
















APPENDIX 5- CONSENT FORM FOR TB DIAGNOSTICS PRIMARY STUDY 
 
 





Institute of Infectious Diseases and Molecular 
Medicine 
Faculty of Health Sciences 
Observatory 7925 
South Africa 
Tel: +27 (0)21 406 6084 
 
Robert J Wilkinson MA PhD BM BCh DTM&H 
FRCP 
Wellcome Trust Senior Fellow in Clinical Tropical 
Medicine 





Increasing prevention and treatment of TB through development of a rapid, 
sensitive, and affordable biological marker (genomic or proteomic) for 
diagnosis of TB in HIV positive and negative populations. 
 
 
INFORMED CONSENT and INFORMATION FORM 
 
My name is _______________________ 
 
I wish to invite you to participate in a study that is trying to produce new blood 
tests to diagnose tuberculosis (TB). This study is being run by the Institute of 
Infectious Diseases and Molecular Medicine at the University of Cape Town. Dr 
Robert J Wilkinson is the Principal Investigator. 
 















TB is a disease that is seen very commonly in Cape Town and, indeed, in most 
of South Africa. It is caused by bacteria that people breathe in and the infection 
results in cough, fevers and weight loss. The disease can be more severe in 
patients with HIV infection. 
 
Early diagnosis and treatment of TB can save lives. The current methods of 
diagnosing TB can take up to two months and are not always successful in 
diagnosing TB in patients with HIV, although these patients are the ones who 
need most urgent treatment.  
 
A skin test is sometimes used although its reliability is not very good especially in 
HIV infected people. We are therefore looking at new blood tests which may help 
us to diagnose TB very quickly (within 2-3 days). We want to compare these 
tests with the skin test and the other usual methods to diagnose TB. We hope 
these tests will help us identify patients in urgent need of TB medicines in the 
future without having to wait several weeks for their culture reports. 
 
We request your participation in this study because you are being investigated 
for TB as a possible cause for your illness. You have also undergone voluntary 
counselling and testing for HIV infection (VCT) as part of this process. We need 
to know whether you are HIV infected because this can alter the way the test 
performs. The decision regarding your TB treatment will be made by your doctor 
and being a part of this study will not affect your doctor’s decision whether to 
start TB treatment. One of the tests that we would like to do on your sputum 
(spit) is a new test which, if you have TB, we hope will tell us whether this TB is 
resistant to one of the drugs for treatment. If this test shows that this drug might 
not work against your TB, we will use another test to check that this is correct. If 














she/he can change your treatment so that the best drugs for your form of TB can 
be used. 
 
It is entirely up to you to decide whether or not to take part in this study. If you do 
decide to take part, you will be asked to sign this consent form. We will then request 
you to provide us with an extra blood sample (40ml) that can be taken at the same 
time as your normal blood tests.  
 
We will also ask that you have a TB skin test. This skin test is a standard test and 
has been performed on many millions of people. It is done by injecting a small 
amount of fluid under the skin. Over the next 2 days an area of redness and 
hardness at the site of the skin test may develop. This is called induration and we will 
measure it at 48 hours. If this is irritating we can giv  you a cream to stop it. We 
need to see you again in clinic in 2-3 days time to look at your skin test. We will pay 
30 Rand travel expenses for this purpose. If you are HIV infected with no signs of 
active TB but the skin test or blood tests are positive you will be offered six 
months’ treatment to reduce the risk you will develop TB in the future. Although 
blood testing very rarely causes problems, if anything goes wrong the University 
provides insurance to cover this possibility. This study will also be monitored by 
the Research Ethics Committee of the University of Cape Town. Their job is to 
ensure your safety and protect you during the study. 
 
The decision to participate is entirely your own. IF YOU DECIDE NOT TO 
PARTICIPATE, YOUR TREATMENT WILL NOT BE DIASDVANTAGED IN ANY 
WAY. In addition, at any point during the trial you are free to withdraw without 
telling us why. 
 
Since this is a research test, the results will not be made available to the 














other than the doctors and nurses looking after you will know that you are 
participating. Samples will be labelled with code numbers and hence the 
laboratory staff will not know your identity. When the results of the study become 
available, names of the participating patients will not be included. 
 
Do you have any questions? During the study you may contact either the 
Research Ethics Committee (021 406 6492) or Dr Marc Mendelson (021 406 
6793) if you have further questions. Please remember that Dr Mendelson will not 
be directly responsible for your medical care which will be conducted by your 
regular doctors and nurses. 
 
 
Consent to participate in the study: 
 
I have read the above / the above has been read to me and I have had the 
opportunity to discuss the  
 
study with Dr _______________________ and ask any questions. I consent to 


































Date  ______________________ 
 
Name of the Witness _____________________  
 















APPENDIX 6- PROTOCOL SUMMARY OF PRIMARY STUDY 
 
Increasing prevention and treatment of TB through development of a rapid, 
sensitive, and affordable biological marker (genomic or proteomic) for 
diagnosis of TB in HIV positive and negative populations. 
 
Summary 
A simple, affordable diagnostic test for tuberculosis (TB) is urgently needed to 
improve detection of active TB particularly in HIV infected adults and children. 
Improved detection could reduce the global burden of transmission and address 
the key problem of delay in TB diagnosis leading to the increase i  morbidity and 
mortality that characterizes the HIV/TB pandemic in the developing world. The 
major objectives of our programme are (1) to identify a biological marker(s) 
(either gene expression or protein) which distinguish patients with active TB from 
those other diseases prevalent in African populations with high HIV and TB 
prevalence. (2) To develop this marker(s) towards a rapid, simple and affordable 
diagnostic test for active TB, suitable for use in TB control in resource poor 
regions of the world most affected by the HIV pandemic.  
 
As part of a multinational consortium of researchers we have recently been 
awarded a grant totaling € 4.5m to seek biomarkers of active tuberculosis. Work 
in Cape Town to achieve these objectives is envisaged as follows. 
 
Aim 1: Establishment of patient cohorts 
We will recruit adult cohorts of patients (50 per group) in Cape Town, an area of 
high HIV / TB co-infection. The cohorts will be defined as follows: (1) TB+ HIV- 
(2) TB+ HIV+ (3) LTBI (Latent TB) + HIV+ (4) LTBI+ HIV- (5) HIV+ with 
opportunistic infections other than TB (6) HIV- with acute and chronic infections 
other than TB. 














To identify (a) the pattern of gene expression using high density cDNA 
microarrays and (b) protein biomarker(s) using Surface Enhanced Laser 
Disorption Ionisisation Mass Spectrometry (SELDI) in blood collected from 
patient cohorts. Biomarker discovery will focus on the distinction of active TB 
from other disorders prevalent in both HIV infected and uninfected cohorts.  
 
Aim 3: Biomarker characterization  
To identify and characterize (a) the genes (identified in 2a above) and (b) 
proteins (identified in 2b above) that are specific to active TB using bioinformatic 
databases and protein sequencing. 
 
Aim 4: Assay development 
To develop a simple, robust RT-PCR based assay for gene biomarkers identified 
in 3a, and/or an ELISA based protein assay to quantify the candidate protein 
biomarkers identified in 3b.  
 
Aim 5: Validation of Biomarkers 
To validate the diagnostic performance of the defined biomarker assays in larger 
cohorts of (a) children in a separate study and (b) adults with TB, with and 
without concomitant HIV infection or other infections which mimic TB in South 
Africa  
 
Aim 6: Production and Development of Diagnostic assays 
Dissemination and reporting of knowledge and recruitment of industry partners 
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APPENDIX 8- BUDGET AWARD LETTER FOR PRIMARY STUDY 
 
EUROPEAN COMMISSION 
EuropeAid Co<Iperation Office 
Cef1tra1 managemeol of thematic budget Rnes 
Brussel,. 31M A I 2006 
AIDCO O41D (2006) 12341 
Professor Michael Levin 
Brighton and Sussex Medical School 
Medical research building, Brighton 
and Sussex Medical School. University 
of Sussex 
BNI 9PX. Biology road Brighton 
The United Kingdom 
Call for proposals Call for proposal EuropeAidl121404/C/GlMulti "Aid for 
poverty.related diseases (HIV/AIDS, Tuberculosis and 
Malaria) in developing countries" 
Application ref.: SANTE/200S/IOS-061 - 102 
TbemeIJ/lncreasing prevention and treatment ofTB through 
development of a rapid, sensitive and affordable biological 
marker (genomic or proteomic) for diagnosis aCTB in DIV 
positive or negative populations 
Dear Sir, 
With reference to the above application I am pleased to inform you that, on the recommendation 
of the Evaluation Committee, the European Commission has decided that your application may 
be awarded a European Community grant of a maximum € 4532158.00, i.e. 89.85 % of the total 
eligible cost of the action. 
A grant contract between the European Commission and your organisation will therefore be 
prepared. In this connection you will be contacted with a view to finalising it according to the 
recommendations of the Evaluation Committee. 
Please note that this letter does not yet give you the right to the said grant. You will not acquire 
that right until both parties have signed the grant contract, and then your right will depend upon 
the teons of the contract. 
Yours faithfully, 
ak! 
Chainnan of the Evaluation Committee 
Commission eu~nna. B-1049 Bruxelles I Europese Commissie. B·1049 Brussel • Belgium. Telephone: (32·2) 299 11 11. 
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APPENDIX 10- INSTRUCTIONS TO AUTHOR FROM THE INTERNATIONAL JOURNAL OF 
TUBERCULOSIS AND LUNG DISEASE 
1 Original articles on clinical or epidemiological research, intervention evaluation 
(health action, personnel training or health education programmes); 
2 General reviews and technical updates in connection with the elaboration, 
implementation and assessment of national health programmes against 
tuberculosis and lung diseases. 
The IJTLD can also be accessed electronically via the Union website 
(http://www.theunion.org). Access to all back issues is free. Access to the current 
6 months is available to all paid-up members and subscribers using the number 
provided on their current membership card; non-members/non-subscribers can 
access and download individual articles using the ‘Pay-per-view’ option or 
contact The Union (membership@theunion.org) for information on how to 
become a member. 
SUBMISSION OF ARTICLES 
Articles are submitted online via Manuscript Central 
http://mc.manuscriptcentral.com/ijtld. Instructions are given on the site. For 
authors without access to Internet, articles can be sent by e-mail to the Editorial 
Office. 
All other correspondence, such as suggestions for review and perspectives 
articles, should be sent directly to: The Editorial Office, The Union, 68 boulevard 
Saint-Michel, 75006 Paris, FRANCE. e-mail: journal@theunion.org 
Simultaneous submission of a manuscript to more than one journal will 
automatically result in rejection by the IJTLD. 
Each manuscript will be examined by a scientific editor and usually two referees. 
Notification of acceptance or rejection will be sent within 3 months from date of 














later than 3 months after notification. A delayed revised article will be treated as 
a new manuscript. 
The Editor reserves the right to make editorial and literary corrections. 
Any opinions expressed or policies advocated do not necessarily reflect those of 
the Union. 
AUTHORSHIP 
All work must have been approved by all co-authors prior to submission. 
Authorship credit should be based on the following criteria: 1) substantial 
contributions to conception and design, acquisition of data, or analysis and 
interpretation of data; 2) drafting the article or revising it critically for intellectual 
content; and 3) final approval of the version to be published. 
Multicentre groups: When a multicentre group has conducted the study, all 
individuals who accept direct responsibility for the manuscript should be 
identified. When submitting a group author manuscript, the corresponding author 
should clearly identify all individual authors, as well as the group name. 
COPYRIGHT 
The copyright form should be signed and scanned by the corresponding author 
and uploaded directly onto the website with the manuscript on submission. All 
authors must provide a signed form on acceptance. 
PREPARATION OF MANUSCRIPTS 
Manuscripts should conform to the Uniform Requirements for Manuscripts 
submitted to Biomedical Journals (http://www.icmje.org/index.html). Articles on 
clinical research should conform to the standards defined in the Helsinki 
Declaration. 
Authors should ensure that they have followed the relevant recommendations for 
reporting their findings (CONSORT, STARD, MOOSE, STROBE, PRISMA, 
STREGA). 
Details of ethics approval (or a statement that it was not required) should be 














Authors may submit articles in English (US/UK), French or Spanish. Accepted 
articles can be translated into English for publication in the journal. Authors may 
publish in French or Spanish. 
The article should have 1.5 or double spacing and continuous line numbering, 
and, on separate numbered pages: 
Title page: This should contain: 1) a concise, informative title of not more than 
110 characters and spaces, without abbreviations; 2) the names and all 
affiliations of all contributing authors, clearly indicating who is linked to each 
institution; 3) a running head of not more than 45 letters and spaces; 4) a word 
count of the text, excluding summary, references, tables and figures; 5) 3- 5 
keywords that do not appear in the title. 
Summary: An informative structured abstract of not more than 200 words should 
be provided that can be understood without referenc  to the text (see Ann Intern 
Med 1990; 113: 69-76). For optimal clarity, the author should use the headings 
Setting, Objective, Design, Results and Conclusion. Abstracts will be translated 
into the two other languages on acceptance for publication (authors are welcome 
to provide translations). Unstructured summaries may be submitted for review 
articles (250 words) and Short Communications (100 words). 
Text: Headings should be appropriate to the nature of the article. Normally only 
two categories of heading are used. Major headings should be typed in capital 
letters. Minor headings can be typewritten in lower case letters (starting with a 
capital letter) at the left-hand margin. The subtitles should not be numbered 
either with figures or alphabetically. 
The text should be written as objectively as possible. For word limits, please 
refer to the section ‘Length of text’. 
Numerals should be spelt out in full from one to nine (except when referring to a 
measurement), and when beginning a sentence. 















Introduction Setting forth clearly the aim of the study or the main hypothesis, with 
reference to previous studies and indicating the method used. 
Materials or Study population and Methods: NB: Indicate what measures were 
taken to assure the quality of the data. 
Results Presented in logical sequence in the text, with tables and illustrations. All 
the results of the tables should not be repeated in the text; the most important 
results should be emphasised. 
Discussion Related to the aims and results of the study. Conclusions 
2. Other papers can be subdivided as the author desires; the use of headings 
enhances readability. 
Acknowledgements: Acknowledge only persons who have made substantial 
contributions to the study, with their consent, all sources of support in the form of 
grants, and author contributions. 
References (Vancouver format): The accuracy of references is the responsibility 
of the author. They must be numbered in the order in which they are cited in the 
text, and identified by Arabic numerals in superscript. References that are cited 
more than once should retain the same number for each citation. The list of 
references at the end of an article should be arranged in numerical order. NB: 
Numbering in tables/figures corresponds to where the tables/figures are cited in 
the text. 
The only acceptable references are those of publications that can be consulted. 
References to an article in a periodical should include the names of the authors, 
followed by their initials (list all authors when six or fewer; when there are more, 
list only the first three and add ‘et al.’), the full title of the article in its original 
language, the name of the journal in its usual abbreviated form (Index Medicus), 
year of publication, tome or volume number, first and last page numbers in full: 
e.g., Gordon J B, Bennett A M. Tuberculosis in reindeer. Scand Rev 
Respir Dis 1978; 96 (Suppl): 217-219.  References to a piece of work 














the names of the authors as above, the title of the piece of work in its original 
language, the number of the publication, the name of the editor, the place and 
year of publication, the number of the volume and the first and last page 
numbers. 
References to a chapter in a book should include the names of the authors as 
above, the title of the chapter with the word "In" preceding the reference of the 
work as above. 
e.g., Girling D J. The chemotherapy of tuberculosis. In: Ratledge C, Stanford J, 
Grange J M, eds. Biology of the mycobacteria. London, UK: Academic Press, 
1989: pp 285-323. 
Electronic references should be given only when an original citation is 
unavailable; as much information should be provided as possi- ble, including 
html address and date of access. 
References to an article to be published should give the name of the journal with 
the mention ‘(in press)’ and only appear after having been accepted. Articles 
under submission can be cited in the text. 
Personal communications should be given in the text with the name of the 
individual cited and with his/her consent. 
TABLES 
Tables should be referr d to consecutively in the text and placed after the 
references. They should be numbered in Arabic numerals which are used for 
reference in the text. A short descriptive title should appear above the table. 
Each column should have a short or abbreviated title. All abbreviations should be 
explained in a clear legend below the table. The number and size of the tables 
should be kept to a basic minimum to explain the most significant results. 
FIGURES 
Figures should be referred to consecutively in the text. They can be inserted into 
the Word document (after the tables) or uploaded separately as image files (.jpg, 














Line drawings (curves, diagrams, histograms) should be in black and white, with 
solid black lines. For optimal clarity avoid shading. 
The size of the symbols and lettering should be in scale with the figure. A sans 
serif font, such as Arial, should be used and be of uniform size. All figures should 
be the same point size.  Half-tone figures should be clear and highly contrasted 
in black and white. Photo-micrographs should have internal scale markers where 
appropriate. X-ray films should bring out the detail to be illustrated with the area 
of importance clearly indicated. 
Techniques (staining, magnification, etc) should be defined.  The cost of 
reproducing colour illustrations (print or online) will be 
covered by the authors. 
Half tone and colour figures should be supplied at a resolution of a least 300 dpi 
(preferably 500 dpi). 
Every Figure should have a brief explanatory legend that does not repeat 
information given in the text. 
Patient confidentiality Where illustrations show recognisable individuals, consent 
must be obtained for publication. If not es- sential to the illustration, authors 
should indicate where it can be cropped, or mask the eyes. 
After acceptance, figures should be supplied in editable format (e.g., .ppt, .xls) to 
allow editorial modifications. 
Permission to reproduce illustrations or tables should be obtained from the 
original publishers and authors, and submitted with the article. They should be 
acknowledged as follows: ‘Reproduced with the kind permission of (publishers) 
from (reference)’. 
ABBREVIATIONS AND UNITS 
Avoid abbreviations in the title or summary. Abbreviations or unusual terms 
should be described at the first time of use. 
Symbols and units of measure must conform to recognised scientific use, i.e., SI 














Society of Medicine publication Units, Symbols and Abbreviations: A Guide for 
Biological and Medical Editors and Authors. 
Designation of diseases must conform to the International Classification of 
Diseases. Designation of micro-organisms must con- form to the norms of 
biology. Proprietary names of drugs, instruments, etc., should be indicated by 
the use of initial capital letters. Names of instruments should be accompanied by 
the manufacturer's name, city, state and country. 
LENGTH OF TEXT 
Original articles: text up to 2500 words, a structured summary of 200 words, 7 
moderate-sized tables/figures and 35 references. 
Review articles: text up to 4500 words, a structured or unstructured summary of 
250 words, 8 moderate-sized tables/figures and 90 references. Pre-submission 
query required with one- page proposal. Submitted to peer review. 
Editorials: text up to 500 words and 5 references. Editorials are usually invited. 
Perspective articles: text up to 2500 words and 35 references. Pre-submission 
query required with one-page proposal. 
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